Introduction
============

Obesity contributes to the etiology of a variety of comorbid conditions, such as type 2 diabetes, hypertension and cardiovascular disease ([@b1-ijmm-40-03-0784]). Inflammation and metabolism in adipose and non-adipose tissues are affected by a variety of adipokines secreted by adipose tissues. Modulating the endocrine functions of adipose tissue contributes to chronic inflammation, which can cause associated disorders, specifically insulin resistance ([@b2-ijmm-40-03-0784]). The incidence of obesity associated with metabolic syndrome has increased worldwide and is likely the result of high-calorie diets and limited physical inactivity ([@b3-ijmm-40-03-0784]). Estimates suggest that this population may double to \>300 million by the year 2025 ([@b4-ijmm-40-03-0784]). An increase in the regional distribution of body fat, i.e., abdominal obesity, can cause obesity ([@b5-ijmm-40-03-0784]). It results in the clustering of atherogenic risk factors, i.e., dyslipidemia, hypertension, inflammatory cytokine profiles, alterations in coagulation and hyperinsulinemic insulin resistance.

The morbidity and mortality rates from cardiovascular disease have increased ([@b6-ijmm-40-03-0784]). The accumulation of triglycerides (TGs) in many tissues is caused by the excessive intake of fatty acids, i.e., lipolysis caused by the accumulation of fat tissues. An increased circulation of fatty acids increases the risk of lipolysis in adipocytes and insulin resistance, resulting in a plethora of fatty acids stored in non-adipose tissues, such as the liver, pancreas and muscle. Increased levels of fatty acid binding and transport proteins in adipose and non-adipose tissues facilitate promote insulin resistance. The high availability of free fatty acids (FFAs) and their deposition in muscle induces a negative loop of insulin-mediated muscle insulin signaling and glucose utilization. The continued exposure of the pancreas to FFAs can impair insulin release through a lipotoxic mechanism ([@b7-ijmm-40-03-0784]). High FFA concentrations contribute to resistance to insulin action in the liver by enhancing hepatic glucose output ([@b8-ijmm-40-03-0784]). Non-alcoholic fatty liver disease (NAFLD) can be caused by the accumulation of TGs in the liver. NAFLD damages the liver, the main glucose metabolizing organ, and can cause hepatocellular necrosis steatosis, fibrosis and steatohepatitis ([@b9-ijmm-40-03-0784]). A balance between hepatic lipolysis and lipogenesis is important to prevent insulin resistance and NAFLD, which are characteristics of metabolic syndrome ([@b10-ijmm-40-03-0784]).

However, currently available pharmacological means for the treatment of metabolic syndrome have a number of limitations, i.e., high rates of secondary failure and adverse effects ([@b11-ijmm-40-03-0784]). Therefore, physicians are increasingly considering complementary and alternative approaches for patients with metabolic syndrome ([@b12-ijmm-40-03-0784],[@b13-ijmm-40-03-0784]).

Simvastatin is a lipid-lowering statins that inhibits HMG-CoA reductase ([@b14-ijmm-40-03-0784],[@b15-ijmm-40-03-0784]). Although simvastatin does not or only slightly increases blood insulin and glucose levels in animals and humans ([@b16-ijmm-40-03-0784],[@b17-ijmm-40-03-0784]), it has been used in the treatment of dyslipidemia and in the prevention of cardiovascular disease in patients with diabetes ([@b18-ijmm-40-03-0784],[@b19-ijmm-40-03-0784]) and has beens hown to exert favorable antioxidant effects on high-fat diet (HFD)-fed rats ([@b20-ijmm-40-03-0784],[@b21-ijmm-40-03-0784]). However, simvastatin can cause various side-effects, including joint pain, memory loss and myopathies ([@b22-ijmm-40-03-0784],[@b23-ijmm-40-03-0784]). Simvastatin (10 mg/kg) was selected as a reference drug in this study, at a dose level based on our previous HFD-fed mouse studies ([@b12-ijmm-40-03-0784],[@b13-ijmm-40-03-0784]).

Bioactive proteins are small amino acid sequences derived from food proteins having potential physiological properties ([@b24-ijmm-40-03-0784]). Fish hydrolysates are another beneficial protein supplement that is useful for the treatment of a variety of clinical conditions ([@b24-ijmm-40-03-0784],[@b25-ijmm-40-03-0784]). Fish hydrolysates have anti-proliferative, anti-microbial and antioxidant effects ([@b26-ijmm-40-03-0784]). In particular, some protein hydrolysates have been shown to have anti-obesity and hypolipidemic effects in HFD-fed obese animals ([@b27-ijmm-40-03-0784]--[@b30-ijmm-40-03-0784]). The yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) is a bagrid catfish that inhabits Eastern Asia from Siberia to China, Korea, Vietnam and Laos, where it can be found in lakes and river channels. This catfish reaches a maximum weight of 3 kg and a length of 34.5 cm, although it is much more commonly found in lengths of 8 cm. It is a minor edible component in commercial fisheries ([@b31-ijmm-40-03-0784],[@b32-ijmm-40-03-0784]).

In the present study, we reported that yellow catfish protein hydrolysate (YPh) exerts anti-obesity effects, attenuating related complications in obese mice with mild diabetes fed a 45% kcal HFD ([@b12-ijmm-40-03-0784],[@b33-ijmm-40-03-0784]--[@b35-ijmm-40-03-0784]).

Materials and methods
=====================

Animals and husbandry
---------------------

Female specific pathogen-free ICR mice (age, 6 weeks at receipt; OrientBio, Seungnam, Korea) were used following a 7-day acclimatization period. The animals were allocated 4--5 per polycarbonate cage in a temperature (20--25°C)- and humidity (40--45%)-controlled room. The light:dark cycle was 12:12 h, and commercial rodent feed (Samyang Feed, Seoul, Korea) and water were supplied *ad libitum*. Animals that had completed a 1-week adaption period prior to being fed the HFD were allocated to 1 of 6 groups (n=8/group, a total of 48 HFD-fed mice and normal diet fed mice) based on body weight (intact control: mean, 29.26±1.95 g; range, 26.00--32.20 g; HFD-fed group: mean, 32.07±1.45 g; range, 29.70--35.80 g). All laboratory animals were treated according to the national regulations of the usage and welfare of laboratory animals, and approved by the Institutional Animal Care and Use Committee in Daegu Haany University (Gyeongsan, Gyeongbuk, Korea) (approval no. DHU2015-016).

Preparation and administration of test substances
-------------------------------------------------

The yellow catfish were kindly provided by an aquaculture farm (Gimje-si, Jeollabuk-do, Korea). They were placed in sterilized polyethylene bags (vacuum-packed; 450×650 mm) securely packed in polystyrene containers, and transported to Silla University (Busan, Korea) at 5°C using frozen ice packs within 4 h. The light yellow-colored YPh powder was prepared as follows: briefly, fish tissues were warmed to 50°C for 10 min, mixed with a 5-fold volume of distilled water, and reacted with Alcalase (E/S, 3.6 AU/g) at 50°C for 10 min (100 rpm shaking). The enzyme activities were then inhibited by heating in a water bath for 15 min. Finally, the mixture was centrifuged at 4,000 rpm for 10 min, and the supernatant was completely lyophilized. The YPh was stored at −20°C to protect it from light and humidity until use. Simvastatin (Bicon Ltd., Bangalore, India) was used as a recommended reference drug. YPh (500, 250 and 125 mg/kg) was dissolved in distilled water and orally administered once daily for 84 days beginning 7 days after the acclimatization to the HFD. Simvastatin (10 mg/kg) was also orally administered. Equal volumes of distilled water were orally administered to an intact vehicle and HFD-fed control mice ([Fig. 1](#f1-ijmm-40-03-0784){ref-type="fig"}). The doses of YPh (500, 250 and 125 mg/kg) were selected based on *in vivo* efficacy tests of other protein hydrolysates in HFD-fed obese animals performed by other investigators ([@b27-ijmm-40-03-0784]--[@b30-ijmm-40-03-0784]).

HFD
---

The mice were adapted to the 45%/kcal HFD (Research Diet, New Brunswick, NJ, USA) ([Table I](#tI-ijmm-40-03-0784){ref-type="table"}) for 7 days and fed this diet during the experiment. A normal pelleted diet (Superfeed Co., Seoul, Korea) was supplied to the intact controls.

Changes in body weight
----------------------

Changes in the body weight of the mice were measured after 8 days (immediately before the commencement of the HFD feeding), 1 day prior to the administration of YPh and simvastatin (10 mg/kg), and weekly until termination using an automatic electronic balance (Precisa Instrument, Dietikon, Switzerland). All experimental animals were fasted overnight (no water for 12 h) at the beginning and end of the feeding trial to reduce differences in the measured values from feeding. Body weight gain was calculated during the adoption (days 8-0 prior to the trial) and administration periods (days 0--84 of the test substance administration), as described below in [equation \[1\]](#fd1-ijmm-40-03-0784){ref-type="disp-formula"} and [equation \[2\]](#fd2-ijmm-40-03-0784){ref-type="disp-formula"}: $$\text{Body~weight~gain}(g)\text{during~the}7\text{-day~adaptation~period} = \lbrack\text{body~weight~at~administration} - \text{body~weight~when~fed~the~HFD}(\text{from}\ 0–8\ \text{days~before~the~test~substance~administration})\rbrack$$ $$\text{Body~weight~gain}(g)\text{during~the}\ 84\text{-day~administration~period} = \lbrack\text{body~weight~at~termination} - \text{body~weight~at~administration}(\text{from}\ 0–84\ \text{days~of~the~test~article~administration})\rbrack$$

Mean daily food consumption
---------------------------

A 150 g food/cage was supplied and the quantity remaining in each cage was measured after 24 h using an automatic electronic balance. The individual mean daily food consumption by the mice (g/day/mice) was determined using [equation \[3\]](#fd3-ijmm-40-03-0784){ref-type="disp-formula"} as follows: $$\text{Mean~daily~food~consumption}(g/\text{day}/\text{mice}) = \frac{\text{Quantity~of~diet~supplied}(150g) - \text{Quantity~of~remaining~diet~after}24h}{(\text{Reared~head~of~mice})}$$Measurements were taken once a week during the 84-day administration period.

Measurement of body fat density: Total and abdominal fat mass (%)
-----------------------------------------------------------------

Mean whole body and abdominal fat densities were measured in all mice using dual-energy X-ray absorptiometry (DXA; InAlyzer, Medikors, Seungnam, Korea) once after the 84-day test substance treatment was completed ([Fig. 2](#f2-ijmm-40-03-0784){ref-type="fig"}).

Serum biochemistry
------------------

Blood was collected from the caudal vena cava after the 84 days of treatment, placed in clotting activated serum tubes, and centrifuged at 15,000 rpm for 10 min at room temperature. The serum was collected for the later analyses of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), total cholesterol (TC), creatinine, low-density lipoprotein (LDL), TG, high-density lipoprotein (HDL) and creatinine levels. Serum BUN, ALT, creatinine, AST, TG and TC levels were measured using an automated blood analyzer (Hemagen Analyst; Hemagen Diagnostic, Columbia, MD, USA) and serum LDL and HDL levels were detected using another type of automated blood analyzer (AU400; Olympus, Tokyo, Japan).

Measurement of organ weight
---------------------------

The weights of the pancreas, liver, left periovarian fat pads, left kidney and abdominal wall-deposited fat pads attached to the muscularis quadratus lumborum were measured individually at sacrifice at day 84, and relative weights (% body weight) were calculated using body weight at sacrifice and absolute weight to decrease differences among individual body weights.

Measurement of fecal lipid composition
--------------------------------------

Lipids were extracted from feces collected after 8 h of the last test substance administration, according to the method of Folch *et al* ([@b36-ijmm-40-03-0784]). Fecal TG and TC concentrations were measured using a commercial enzyme kit (Asan Pharmaceutical Co., Seoul, Korea) based on a modification of the lipase-glycerol phosphate oxidase method ([@b37-ijmm-40-03-0784]--[@b39-ijmm-40-03-0784]).

Liver lipid peroxidation and antioxidant defense systems
--------------------------------------------------------

The glutathione (GSH) and malondialdehyde (MDA) contents, as well as the superoxide dismutase (SOD) and catalase (CAT) activities, were assessed in mouse hepatic tissues. Separate liver tissues were weighed and homogenized in ice-cold 0.01 M Tris-HCl (pH 7.4) and centrifuged at 12,000 × g for 15 min as previously described by Kavutcu *et al* ([@b40-ijmm-40-03-0784]). The degree of liver lipid peroxidation was measured by estimating the MDA content using the thiobarbituric acid test at an absorbance of 525 nm (nM MDA/mg tissue) ([@b41-ijmm-40-03-0784]). Total protein contents were measured using a previously reported method ([@b42-ijmm-40-03-0784]), with bovine serum albumin (Invitrogen, Carlsbad, CA, USA) as the internal standard. The homogenates were mixed with 0.1 ml 25% trichloroacetic acid (Merck, San Francisco, CA, USA) and centrifuged at 4,200 rpm for 40 min at 4°C. The GSH contents were measured at an absorbance of 412 nm using 2-nitrobenzoic acid (Sigma-Aldrich, St. Louis, MO, USA) and reported as *µ*M/mg tissue ([@b43-ijmm-40-03-0784]). The decomposition of H~2~O~2~ in the presence of CAT was monitored at 240 nm ([@b44-ijmm-40-03-0784]). CAT activity was defined as the amount of enzyme required to decompose 1 nM of H~2~O~2~ per min at 25°C and pH 7.8. The results were expressed as U/mg tissue. SOD activity was measured as previously described by Sun *et al* ([@b45-ijmm-40-03-0784]). SOD estimates were based on the generation of superoxide radicals produced by xanthine and xanthine oxidase, which react with nitro tetrazolium blue to form a blue formazan dye. SOD activity was measured at 560 nm based on the degree of inhibition of this reaction and was expressed as U/mg tissue. One unit of SOD enzymatic activity was equal to the amount of enzyme that diminishes the initial absorbance of nitroblue tetrazolium by 50% over 1 min.

Histopathological examination
-----------------------------

The left kidney and the left lateral lobe of the liver, the left periovarian fat pads, the splenic lobe of the pancreas and the abdominal wall-deposited fat pads attached to the muscularis quadratus lumborum were fixed in 10% neutral buffered formalin. After embedding in paraffin, 3--4 *µ*m-thick serial sections were prepared and stained with hematoxylin and eosin (H&E) for light microscopic examination. The histological profiles of individual organs were described. Portions of the liver that had been dehydrated in 30% sucrose were sectioned by cryostat for Oil Red O staining ([@b39-ijmm-40-03-0784],[@b46-ijmm-40-03-0784]). To observe more details of the histopathological changes, the steatohepatitis region and mean hepatocyte diameters (by H&E staining) were calculated using an automated imaging analysis program (*i*Solution FL ver. 9.1; IMT *i*-Solution Inc., Vancouver, QC, Canada) according to previously reported methods ([@b12-ijmm-40-03-0784],[@b13-ijmm-40-03-0784],[@b39-ijmm-40-03-0784],[@b46-ijmm-40-03-0784]). The regions of steatohepatitis and percentage of fat-deposited regions in the hepatic parenchyma were calculated as percentages of lipid deposited regions (%/mm^2^ of hepatic parenchyma). The sections were cut using a cryostat, stained with Oil Red O, and mean hepatocyte diameters were calculated using an automated image analysis process; at least 10 hepatocytes per liver field of view were considered. In addition, the mean number of lipid droplets deposited in vacuolated renal tubules was calculated using an automated image analysis process among 100 tubules (number/100 tubules in one field/sample). The mean diameter of white adipocytes in the fat pads was calculated using an automated image analysis process; at least 10 white adipocytes per fat pad were considered. Mean area occupied by zymogen granules (%/mm^2^ of pancreatic parenchyma), thicknesses of the periovarian and abdominal wall fat pad (mm) deposits, diameters of pancreatic islets and number of pancreatic islets (islets/10 mm^2^ of pancreatic parenchyma) were measured according to our previously established methods ([@b12-ijmm-40-03-0784],[@b13-ijmm-40-03-0784],[@b39-ijmm-40-03-0784]). The histopathologist was blinded to the group distribution.

Immunohistochemistry
--------------------

Other serially prepared sectioned pancreatic tissues were immunostained using the avidin-biotin-peroxidase (ABC) method as previously described by Kang *et al* ([@b39-ijmm-40-03-0784]), with guinea pig polyclonal insulin (dilution 1:2,000) or rabbit polyclonal glucagon (dilution 1:2,000) (both from DiaSorin, Stillwater, MN, USA) antiserum. Briefly, endogenous peroxidase activity was blocked by incubation in methanol and 0.3% H~2~O~2~ for 30 min. Non-specific immunoglobulin binding was blocked with a normal horse serum blocking solution (dilution 1:100; Vector Laboratories, Burlingame, CA, USA) for 1 h in a humidity chamber. The primary antiserum was incubated overnight at 4°C in a humidity chamber and then incubated with the biotinylated universal secondary antibody (dilution 1:50; cat. no. PK-6200; Vectastain Elite ABC kit) and ABC reagents (Vectastain Elite ABC kit; dilution 1:50) (both from Vector Laboratories) for 1 h at room temperature in a humidity chamber. Finally, the tissues were subjected to a peroxidase substrate kit (Vector Laboratories) for 3 min at room temperature. All sections were rinsed 3 times between steps in 0.01 M phosphate-buffered saline (PBS). Cells with \>20% immunoreactivity were regarded as positive compared with other naïve cells, and the mean numbers of insulin- and glucagon- immunoreactive cells dispersed in the pancreatic parenchyma were counted using an automated image analysis process, as previously described ([@b39-ijmm-40-03-0784],[@b47-ijmm-40-03-0784]) and the ratio was calculated using [equation \[4\]](#fd4-ijmm-40-03-0784){ref-type="disp-formula"} as follows: $$\frac{\text{Insulin}}{\text{Glucagon}}\text{cells}(\text{ratio}) = \frac{\text{Mean~number~of~insulin} - \text{immunoreactive~cells}}{\text{Mean~number~of~glucagon~immunoreactive~cells}}$$

Statistical analyses
--------------------

All numerical values were expressed as the means ± standard deviation of 8 mice. The results of the different dose groups were analyzed using a multiple comparison tests. The variance was examined using the Levene test ([@b48-ijmm-40-03-0784]). If the Levene test indicated no significant deviations from homogeneity, the data were analyzed by a one-way analysis of variance followed by a least significant difference (LSD) multi-comparison test to determine which pairs were significantly different. The non-parametric Kruskal-Wallis H test was conducted when the variance was heterogeneous as indicated by significant deviations from observed values on the Levene test. When a significant difference was observed in the Kruskal-Wallis H test, The Mann-Whitney U test was conducted to determine the specific pairs that were significantly different. Statistical analyses were conducted using SPSS version 14 (SPSS Inc., Chicago, IL, USA) ([@b49-ijmm-40-03-0784]). In addition, the percentage changes were calculated and compared with the HFD-fed control to examine the efficacy of the test substances, and the percentage changes between the intact and HFD-fed controls were calculated to observe disease, as described below using [equation \[5\]](#fd5-ijmm-40-03-0784){ref-type="disp-formula"} and [\[6\]](#fd6-ijmm-40-03-0784){ref-type="disp-formula"} according to our previous study ([@b39-ijmm-40-03-0784]). $$\text{Percentage~change~compared~with~intact~control}(\%) = \frac{\text{HFD~control~data} - \text{Intact~control~data}}{\text{Intact~control~data}} \times 100$$ $$\text{Percentage~change~compared~with~HFD~control}(\%) = \frac{\text{Test~substance~administered~mice~data} - \text{HFD~control~data}}{\text{HFD~control~data}} \times 100$$

Results
=======

Effects on obesity
------------------

### Changes in body weight

The body weights of the HFD-fed control mice increased significantly (p\<0.01) as compared with the intact mice (fed the normal diet) after 1 week. Accordingly, body weight gain increased significantly (p\<0.01) from 7 days after adapting to the HFD through day 84 of administration compared with the intact control group. However, a significant (p\<0.01 or p\<0.05) decrease in body weight was detected in the 10 mg/kg simvastatin- and 500 and 250 mg/kg YPh-treated mice beginning at 21 days after the administration began compared with the HFD untreated control. Thus, the body weight gain during the 84-day administration period decreased significantly (p\<0.01) in these groups compared with the HFD-fed control. In addition, the 125 mg/kg YPh-treated mice also lost a significant (p\<0.01 or p\<0.05) amount of body weight beginning 28 days after the initial administration and experienced a significant (p\<0.01) decrease in body weight gain during the 84-day administration period, compared with HFD-fed control mice ([Fig. 1](#f1-ijmm-40-03-0784){ref-type="fig"} and [Table II](#tII-ijmm-40-03-0784){ref-type="table"}).

### Effects on food consumption

Mean daily food consumption decreased significantly (p\<0.01) in all HFD-fed mice compared with the intact control; however, no changes in mean daily food consumption were detected in any of the test substance-administered groups compared with the HFD-fed control ([Table II](#tII-ijmm-40-03-0784){ref-type="table"}).

### Effects on body fat density: total and abdominal fat mass (%)

Total body and abdominal fat density increased significantly (p\<0.01) in the HFD-fed control compared with the intact control groups. By contrast, total body and abdominal fat mass decreased significantly (p\<0.01) in the 10 mg/kg simvastatin- and YPh, 125, 250 and 500 mg/kg-treated mice compared with the HFD-fed control mice according to the DXA results ([Figs. 2](#f2-ijmm-40-03-0784){ref-type="fig"} and [3](#f3-ijmm-40-03-0784){ref-type="fig"}).

### Effects on periovarian-deposited fat pad weight

Periovarian-deposited fat pad weight increased significantly (p\<0.01) in the HFD-fed control group compared with the intact control group. However, the increase (p\<0.01) in absolute and relative weight decreased significantly in response to all test substances, including 500 mg/kg YPh ([Table III](#tIII-ijmm-40-03-0784){ref-type="table"} and [Fig. 2](#f2-ijmm-40-03-0784){ref-type="fig"}).

### Effects on abdominal wall-deposited fat pad weight

The absolute and relative weight of the abdominal wall-deposited fat pads increased significantly (p\<0.01) in the HFD-fed control mice compared with the intact controls. However, the increase in abdominal wall-deposited fat pad weight decreased significantly (p\<0.01) in response to all test substances ([Table III](#tIII-ijmm-40-03-0784){ref-type="table"} and [Fig. 2](#f2-ijmm-40-03-0784){ref-type="fig"}).

### Effects on adipocyte histopathology in periovarian- and abdominal wall-deposited fat pads

Periovarian and abdominal white adipocyte diameters and fat pad thickness increased significantly (p\<0.01) in the HFD-fed control mice compared with the intact controls. However, adipocyte hypertrophy and the fat deposits were significantly (p\<0.01) inhibited by all test substances, including 10 mg/kg simvastatin, compared to the HFD-fed control group ([Table IV](#tIV-ijmm-40-03-0784){ref-type="table"} and [Fig. 4](#f4-ijmm-40-03-0784){ref-type="fig"}).

Effects on the pancreas
-----------------------

### Effects on pancreatic weight

Relative pancreatic weight decreased significantly (p\<0.01) in the HFD-fed control mice compared with the intact control mice; however, relative pancreatic weight increased significantly (p\<0.01) in the mice treated with 10 mg/kg simvastatin and 500, 250 and 125 mg/kg YPh compared with the HFD-fed control mice. No changes in absolute pancreatic weight were detected in any of the experimental HFD-fed mice, including the control mice compared with the intact controls ([Table III](#tIII-ijmm-40-03-0784){ref-type="table"}).

### Effects on exocrine pancreas zymogen granule content

The exocrine pancreas zymogen granule content decreased significantly (p\<0.01) in the HFD-fed controls compared with the intact controls fed the NFD, resulting from the release of zymogen granules. However, the exocrine pancreas zymogen granule content increased significantly (p\<0.01) in all test drug-treated mice compared to the HFD-fed control, apart from the 10 mg/kg simvastatin-treated mice, in which the percentage of exocrine pancreas occupied by zymogen granules only increased slightly compared to the HFD-fed control mice ([Table V](#tV-ijmm-40-03-0784){ref-type="table"} and [Fig. 5](#f5-ijmm-40-03-0784){ref-type="fig"}).

Effects on hyperlipidemia
-------------------------

### Effects on serum TC levels

A significant (p\<0.01) increase in serum TC levels was detected in the HFD-fed controls compared to the intact controls. However, the serum TC levels decreased significantly (p\<0.01) in all the test substance-treated groups, including the mice treated with 500 mg/kg YPh, compared to the HFD-fed controls ([Table VI](#tVI-ijmm-40-03-0784){ref-type="table"}).

### Effects on serum TG levels

A significant (p\<0.01) increase in serum TG levels was detected in the HFD-fed controls compared to the intact controls. However, the serum TG levels decreased significantly (p\<0.01) in all of the test substance-treated groups, including the 250 mg/kg YPh-treated mice, compared to the HFD-fed controls ([Table VI](#tVI-ijmm-40-03-0784){ref-type="table"}).

### Effects on serum LDL levels

A significant (p\<0.01) increase in serum LDL levels was observed in the HFD-fed controls compared to the intact controls. However, the serum LDL levels decreased significantly (p\<0.01) in all the test substance-treated mice, including the mice that received 10 mg/kg simvastatin compared to the HFD-fed controls ([Table VI](#tVI-ijmm-40-03-0784){ref-type="table"}).

### Effects on serum HDL levels

A significant (p\<0.01) decrease in serum HDL levels was detected in the HFD-fed controls compared to the intact controls. However, the serum HDL levels increased significantly (p\<0.01) in all test substance-treated HFD-fed mice compared with the HFD-fed control mice ([Table VI](#tVI-ijmm-40-03-0784){ref-type="table"}).

### Effects on fecal TG and TC contents

Although a slight increase in the fecal TG and TC contents was detected in the HFD-fed controls compared with the intact controls fed the NFD, the fecal TG and TC contents in all the test substance-treated mice, including those treated with 500 mg/kg YPh, increased significantly (p\<0.01) compared to HFD-fed control mice ([Fig. 6](#f6-ijmm-40-03-0784){ref-type="fig"}).

Effects on hepatopathy
----------------------

### Effects on liver weight

A significant (p\<0.01) increase in absolute liver weight was detected in the HFD-fed controls compared to the intact controls. However, this increase was significantly (p\<0.01) normalized by treatment with all the test substances compared to the HFD-fed control mice. No changes in relative liver weight were observed in the HFD-fed control mice compared to the intact control mice, and no changes in relative liver weight were observed in any of the test substance-treated mice compared with the HFD-fed control mice ([Table III](#tIII-ijmm-40-03-0784){ref-type="table"}).

### Effects on serum AST levels

A significant (p\<0.01) increase in serum AST levels was detected in the HFD-fed controls compared with the intact controls. However, the serum AST levels decreased significantly (p\<0.01) in all the test substance-treated mice compared with the HFD-fed controls ([Table VII](#tVII-ijmm-40-03-0784){ref-type="table"}).

### Effects on serum ALT levels

A significant (p\<0.01) increase in the serum ALT levels was detected in the HFD-fed controls compared with the intact controls. However, the serum ALT levels decreased significantly (p\<0.01) in all the test substance-treated mice, including those treated with 10 mg/kg simvastatin, compared with the HFD-fed controls ([Table VII](#tVII-ijmm-40-03-0784){ref-type="table"}).

### Effects on steatohepatitis

A significant (p\<0.01) increase in steatohepatitis (percentage of fat-affected regions in the liver parenchyma) was detected in the HFD-fed controls compared with the intact controls, resulting from the severe hypertrophy of hepatocytes related to intracellular lipid deposition. However, steatohepatitis was significantly (p\<0.01) normalized following treatment of the mice with the test substances ([Table V](#tV-ijmm-40-03-0784){ref-type="table"} and [Fig. 7](#f7-ijmm-40-03-0784){ref-type="fig"}).

### Effects on hepatocyte hypertrophy

A significant (p\<0.01) increase in mean hepatocyte diameter (hypertrophy) was detected in the HFD-fed controls compared with the intact controls. However, hypertrophy decreased significantly (p\<0.01) in all test substance-treated mice compared with the HFD-fed controls ([Table V](#tV-ijmm-40-03-0784){ref-type="table"} and [Fig. 7](#f7-ijmm-40-03-0784){ref-type="fig"}).

Effects on nephropathy
----------------------

### Effects on kidney weight

A significant (p\<0.01) increase in absolute kidney weight was detected in the HFD-fed control mice compared with the intact controls; however, these effects were significantly (p\<0.01) normalized following treatment with all of the substances compared to HFD-fed mice. No changes in relative kidney weight were observed in the HFD-fed control mice compared with the intact control mice, and no changes in relative kidney weight were observed in any of the test substance-treated mice compared with the HFD-fed control mice ([Table III](#tIII-ijmm-40-03-0784){ref-type="table"}).

### Effects on serum BUN levels

A significant (p\<0.01) increase in serum BUN levels was detected in the HFD-fed controls compared with the intact controls fed the NFD. However, the serum BUN levels decreased significantly (p\<0.01) in all test substance-treated mice compared with the HFD-fed controls ([Table VII](#tVII-ijmm-40-03-0784){ref-type="table"}).

### Effects on serum creatinine levels

A significant (p\<0.01) increase in serum creatinine levels was detected in the HFD-fed controls compared with the intact controls. However, the serum creatinine levels decreased significantly (p\<0.01) in all the test substance-treated HFD-fed mice compared with the HFD-fed control mice ([Table VII](#tVII-ijmm-40-03-0784){ref-type="table"}).

### Effects on kidney histopathology

A significant (p\<0.01) increase in the number of degenerative vacuolated renal tubules was detected in the HFD-fed controls compared with the intact controls, resulting from lipid droplet-deposited diabetic nephropathy; however, these nephropathies were significantly (p\<0.01) normalized by treatment with all of the test substances, including 10 mg/kg simvastatin, compared with the HFD-fed controls ([Table V](#tV-ijmm-40-03-0784){ref-type="table"} and [Fig. 8](#f8-ijmm-40-03-0784){ref-type="fig"}).

Effects on liver lipid peroxidation and the antioxidant defense system
----------------------------------------------------------------------

### Effects on liver lipid peroxidation

A significant (p\<0.01) increase in liver lipid peroxidation (MDA content) was detected in the HFD-fed controls compared with the intact controls; however, these effects were significantly (p\<0.01) normalized by treatment with all of the test substances, including 10 mg/kg simvastatin, compared with HFD-fed control mice ([Table VIII](#tVIII-ijmm-40-03-0784){ref-type="table"}).

### Effects on hepatic GSH content

A significant (p\<0.01) decrease in the content of hepatic GSH, a representative endogenous antioxidant, was detected in the HFD-fed controls compared with the intact controls. However, the hepatic GSH content (p\<0.01) increased significantly in all test substance-treated HFD-fed mice, including the 10 mg/kg simvastatin-treated mice, compared with the HFD-fed control mice ([Table VIII](#tVIII-ijmm-40-03-0784){ref-type="table"}).

### Effects on hepatic CAT activity

A significant (p\<0.01) decrease in the activity of hepatic CAT, a representative endogenous antioxidant enzyme, was detected in the HFD-fed controls compared with the intact controls; however, this decreased activity of CAT was significantly (p\<0.01) normalized by treatment with the test substances compared with the HFD-fed controls ([Table VIII](#tVIII-ijmm-40-03-0784){ref-type="table"}).

### Effects on hepatic SOD activity

A significant (p\<0.01) decrease in the activity of hepatic SOD, another representative endogenous antioxidant enzyme, was detected in the HFD-fed controls compared with the intact controls; however, this effect was significantly (p\<0.01) normalized by treatment with all of the test substances, including 10 mg/kg simvastatin, compared with HFD-fed control mice ([Table VIII](#tVIII-ijmm-40-03-0784){ref-type="table"}).

Discussion
==========

In the present study, we observed the true pharmacological activities of YPh in obese mice with mild diabetes fed a HFD, as previously described ([@b12-ijmm-40-03-0784],[@b33-ijmm-40-03-0784]--[@b35-ijmm-40-03-0784]). Simvastatin (10 mg/kg) is a lipid-lowering medication ([@b14-ijmm-40-03-0784],[@b15-ijmm-40-03-0784]) used in the treatment of dyslipidemia and for the prevention of cardiovascular disease in patients with diabetes ([@b12-ijmm-40-03-0784],[@b13-ijmm-40-03-0784],[@b18-ijmm-40-03-0784],[@b19-ijmm-40-03-0784]). The YPh doses in the present study were selected based on *in vivo* efficacy tests of individual herbal extracts by other investigators. The readily adapted mice to the HFD were selected after a 7-day adaption period and were divided into 6 groups. At the end of 12 weeks of continuous orally administered YPh (500, 250 and 125 mg/kg) or 10 mg/kg simvastatin, the hepatoprotective, hypolipidemic, nephroprotective and anti-obesity effects were analyzed separately.

Obesity in mice develops by feeding on a HFD, having the characteristics of hypolipidemia and hepatic steatosis ([@b12-ijmm-40-03-0784],[@b13-ijmm-40-03-0784],[@b33-ijmm-40-03-0784],[@b34-ijmm-40-03-0784],[@b50-ijmm-40-03-0784],[@b51-ijmm-40-03-0784]). On the other hand, animals fed a HFD develop hyperglycemia and mild obesity and can be used to identify agents that could be used to prevent metabolic syndrome ([@b52-ijmm-40-03-0784]). In this study, we only selected mice that were adapted to the HFD and exhibited a regular increase in body weight compared with the intact controls (normal diet) during the first 7 days of feeding ([Table I](#tI-ijmm-40-03-0784){ref-type="table"}). The HFD-fed control mice exhibited a significant increase in body weight compared with the intact mice, beginning the first 7 days after the HFD feeding began, and body weight gains during the 7 days of adapting to HFD and the 84 days of administration also increased significantly compared with those of the intact controls ([Table II](#tII-ijmm-40-03-0784){ref-type="table"} and [Fig. 1](#f1-ijmm-40-03-0784){ref-type="fig"}). However, the increase in body mass and weight was significantly and dose-dependently inhibited by treatment with simvastatin and YPh ([Table II](#tII-ijmm-40-03-0784){ref-type="table"} and [Fig. 1](#f1-ijmm-40-03-0784){ref-type="fig"}). Obesity is mainly characterized by an increase in fat deposition in the body and the expansion in the intra-abdominal adipose tissues in rodents is caused by cellular hypertrophy ([@b12-ijmm-40-03-0784],[@b13-ijmm-40-03-0784],[@b39-ijmm-40-03-0784],[@b53-ijmm-40-03-0784],[@b54-ijmm-40-03-0784]). Adipose tissue is not simply an energy storage organ, but also an endocrine and secretory organ ([@b55-ijmm-40-03-0784]). Adipokines are secreted by the adipose tissues, and changes in the action, secretion and expression of adipokines are involved in the development of various syndromes, including insulin resistance ([@b39-ijmm-40-03-0784],[@b55-ijmm-40-03-0784],[@b56-ijmm-40-03-0784]). In the present study, treatment with YPh significantly and dose-dependently inhibited the accumulation of fat and adipocyte hypertrophy ([Table III](#tIII-ijmm-40-03-0784){ref-type="table"}), providing direct evidence that YPh has clear anti-obesity effects in HFD-fed mice. In this study, the 10 mg/kg simvastatin-treated mice also exhibited a noticeable decrease in fat accumulation and mean white adipocyte diameter according to the DXA and histopathological analyses ([Table VI](#tVI-ijmm-40-03-0784){ref-type="table"} and [Figs. 2](#f2-ijmm-40-03-0784){ref-type="fig"} and [4](#f4-ijmm-40-03-0784){ref-type="fig"}).

The decrease in mean daily food consumption in all HFD-fed mice compared with those fed the normal diet was not unexpected in our study as the energy content of the HFD (4.73 kcal/g) was much higher (approximately 20-fold) ([Table I](#tI-ijmm-40-03-0784){ref-type="table"}) than that of the normal diet (0.21 kcal/g). A similar decrease in daily food consumption in the HFD-fed mice has been reported ([@b13-ijmm-40-03-0784],[@b39-ijmm-40-03-0784]). In the present study, no changes in mean daily food consumption were detected among all the test substance-administered groups compared with the HFD-fed control ([Table II](#tII-ijmm-40-03-0784){ref-type="table"}), suggesting that it was difficult to use the pharmacological effects of the test substances to consider the effects of lower food consumption.

Obese subjects often develop acinar cell atrophy, pancreatic steatosis and the number of zymogen granules decreases ([@b39-ijmm-40-03-0784],[@b57-ijmm-40-03-0784],[@b58-ijmm-40-03-0784]). An increase in the number of zymogen granules in exocrine pancreatic acinar cells directs the production of lipid and protein digestive enzymes ([@b59-ijmm-40-03-0784]). In the present study, a decrease in the number of pancreatic zymogen granules was also noted in the HFD-fed control mice as compared with the intact controls. However, the decrease in zymogen deposits in the exocrine pancreas was dose-dependently inhibited by YPh treatment, but not by treatment with 10 mg/kg simvastatin ([Table V](#tV-ijmm-40-03-0784){ref-type="table"} and [Fig. 5](#f5-ijmm-40-03-0784){ref-type="fig"}). The findings revealed that YPh exerted anti-obesity effects in HFD-fed mice that may be intervened by inhibiting lipid digestion and decreasing pancreatic enzyme production or release. Simvastatin (10 mg/kg) did not affect the zymogen granule-occupied regions in the exocrine pancreas compared with HFD-fed control mice ([Table V](#tV-ijmm-40-03-0784){ref-type="table"} and [Fig. 5](#f5-ijmm-40-03-0784){ref-type="fig"}).

We could not completely exclude the possibility that YPh increased digestive tract motility; thus, more detailed mechanistic studies are warranted in the future. The rise in digestive tract motility also increases excretion, resulting in a decrease in body weight ([@b60-ijmm-40-03-0784]--[@b62-ijmm-40-03-0784]). In this study, we observed a substantial increase in the fecal TG and TC contents in response to all YPh treatments and 10 mg/kg simvastatin ([Fig. 6](#f6-ijmm-40-03-0784){ref-type="fig"}). The slight increase in fecal TG and TC contents noted in the HFD-fed control mice in this study was considered to be the secondary effects of consuming the HFD.

Hyperlipidemia generally occurs during the chronic progression of diabetes in HFD-fed mice ([@b63-ijmm-40-03-0784]). As the most critical issue in hyperlipidemia is increased serum TC, TG and LDL levels and decreased HDL levels ([@b12-ijmm-40-03-0784],[@b13-ijmm-40-03-0784],[@b64-ijmm-40-03-0784]), the efficacy of hypolipidemic agents is generally evaluated based on the decrease in serum TC, TG and LDL levels as HDL levels increase ([@b12-ijmm-40-03-0784],[@b13-ijmm-40-03-0784],[@b39-ijmm-40-03-0784],[@b65-ijmm-40-03-0784]). In the present study, all 3 doses of YPh (500, 250 and 125 mg/kg) effectively and dose-dependently decreased serum TC, TG and LDL levels, but favorably increased serum HDL levels compared with those in the HFD-fed control mice, suggesting that YPh has favorable hypolipidemic effects in HFD-fed mice, which may be mediated by inhibiting lipid digestion due to the decrease in pancreatic enzyme production or release in this experiment ([Table VI](#tVI-ijmm-40-03-0784){ref-type="table"}). In particular, 250 mg/kg YPh exerted comparable hypolipidemic effects to those of 10 mg/kg simvastatin in HFD-fed mice ([Table VI](#tVI-ijmm-40-03-0784){ref-type="table"}). These hypolipidemic properties of the test substances were also due to decreased lipid absorption and elimination of lipids in feces.

As obesity progresses, liver weight increases due to abnormal glycosylation and fibrosis related to hepatocyte hypertrophy and hepatosteatosis, due to lipid deposition in the cytoplasm along with increased serum ALT and AST levels ([@b13-ijmm-40-03-0784],[@b39-ijmm-40-03-0784],[@b66-ijmm-40-03-0784]). The attenuation of these abnormalities depicts attenuated hepatopathy ([@b66-ijmm-40-03-0784]). AST is detectable in numerous body tissues, but is principally high in striated muscle and the liver. Elevated serum AST activity and no increase in ALT levels indicate muscle necrosis, but AST activity increases more slowly than that of ALT with liver damage. This indicates complete cellular disruption as ALT leaks only from necrotic cells ([@b67-ijmm-40-03-0784]). ALT is present in large quantities in the cytoplasm of hepatocytes and it enters the blood when liver cells are destroyed or damaged. This enzyme is a sensitive indicator of active liver damage, but does not indicate the cause or reversibility of the damage ([@b67-ijmm-40-03-0784]). In the present study, all 3 different YPh doses effectively attenuated hepatopathy compared with the HFD-fed control mice, suggesting that YPh has favorable hepatoprotective effects in HFD-fed mice. Simvastatin also exerted favorable inhibitory effects on the increased liver weight ([Table III](#tIII-ijmm-40-03-0784){ref-type="table"}), serum ALT and AST ([Table VII](#tVII-ijmm-40-03-0784){ref-type="table"}), and related hepatocyte hypertrophic and histopathological steatohepatitis induced by feeding the HFD ([Table V](#tV-ijmm-40-03-0784){ref-type="table"} and [Fig. 6](#f6-ijmm-40-03-0784){ref-type="fig"}).

As obesity progresses, kidney weight also increases due to swelling, inflammation and necrosis along with the elevation of serum creatinine and BUN levels, or so-called nephropathy. The attenuation in these abnormalities is direct evidence of attenuated nephropathy ([@b13-ijmm-40-03-0784],[@b39-ijmm-40-03-0784]). BUN is the amount of urea nitrogen (protein metabolic product) in the blood. High BUN levels generally cause renal disease. Creatinine is a non-protein nitrogenous product of muscle metabolism, and serum creatinine levels increase with conditions that reduce glomerular filtration ([@b67-ijmm-40-03-0784]). In this study, HFD-fed mice exhibited a marked increase in absolute kidney weight and increased creatinine and serum BUN levels with lipid droplet deposition related to vacuolation of the renal tubules, suggesting a mild nephropathy, but they were normalized by all 3 YPh doses and simvastatin, indicating that they have favorable nephroprotective effects ([Tables III](#tIII-ijmm-40-03-0784){ref-type="table"} and [VII](#tVII-ijmm-40-03-0784){ref-type="table"} and [Fig. 8](#f8-ijmm-40-03-0784){ref-type="fig"}).

Considerable evidence indicates a role for free radicals in the altered antioxidant defense in the etiology of diabetes ([@b68-ijmm-40-03-0784]). Diabetes mellitus from its genesis to the development of microvascular complications is affected by oxidative stress. Free radicals are generated by hyperglycemia due to glucose autooxidation. Glycosylated proteins are a source of reactive oxygen species (ROS) ([@b39-ijmm-40-03-0784],[@b69-ijmm-40-03-0784]). Oxidative stress is linked to a decrease in the antioxidant status ([@b70-ijmm-40-03-0784]) which could alter the deleterious effects of free radicals. ROS-related oxidative stress plays an important role in the etiology of complications from obesity ([@b71-ijmm-40-03-0784]). Various toxic substances generated from lipid peroxidation have been demonstrated in HFD-fed mice, where they act as a potent redox cycler by generating harmful ROS and damage organs ([@b73-ijmm-40-03-0784],[@b74-ijmm-40-03-0784]). GSH is a representative endogenous antioxidant that inhibits tissue damage by maintaining ROS at low levels and is a protective antioxidant in tissues ([@b75-ijmm-40-03-0784]).

CAT catalyzes the conversion of H~2~O~2~ to H~2~O and SOD is an antioxidant enzyme that contributes to enzymatic defense mechanisms ([@b76-ijmm-40-03-0784]). Decreased endogenous antioxidants, GSH content and increased lipid peroxidation, antioxidant enzymes, CAT and SOD activities occur in damaged liver tissues, and as a secondary role help to combat obesity and various related complications ([@b77-ijmm-40-03-0784],[@b78-ijmm-40-03-0784]). In this study, a marked depleted GSH content, elevation of hepatic lipid peroxidation, and decreased CAT and SOD activities were noted in the HFD-fed control mice, which was similar to other reported HFD-fed mice studies ([@b79-ijmm-40-03-0784],[@b80-ijmm-40-03-0784]). In the present study, all 3 YPh concentrations dose-dependently inhibited the deterioration in the hepatic antioxidant defense system compared with the HFD=−fed control mice, suggesting favorable antioxidant effects of YPh on HFD mice. Simvastatin also exerted favorable antioxidant effects ([Table VIII](#tVIII-ijmm-40-03-0784){ref-type="table"}).

In conclusion, the results of this study suggest that YPh exerts potent anti-obesity and complication-ameliorating effects in HFD-fed mice by enhancing the modulating effects of hepatic glucose enzyme and antioxidant activities, as well as pancreatic lipid digestive enzymes. The overall effects of 250 mg/kg YPh on HFD-induced diabetes and related complications were similar or more potent than those of 10 mg/kg simvastatin in this study. Accordingly, YPh is a promising novel medicinal ingredient which may has potential for use in the treatment of obesity and related complications.

This study was a component of the project (no. 20130285) entitled \'Development of high value material and bioactive components from freshwater fish\', funded by the Ministry of Oceans and Fisheries, Korea.

![Body weight changes in NFD- or HFD-fed mice. HFD-fed control mice exhibited a significant (p\<0.01) increase in body weight as compared with the intact mice from 1 week after the HFD supply (arrowhead). However, a significant (p\<0.01 or p\<0.05) decrease in body weight was detected in the mice treated with simvastatin 10 mg/kg, and YPh 500 and 250 mg/kg from 21 days after the start of administration as compared with the HFD-fed controls (arrows). In addition, YPh the 125 mg/kg-treated mice exhibited a significant (p\<0.01 or p\<0.05) decrease in body weight from 28 days after the initial administration as compared with the HFD-fed control mice (arrows), in the present study. Values are expressed as the means ± SD of 8 mice. NFD, normal fat pellet diet; HFD, 45% kcal high fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material. Simvastatin was administrated at dose levels of 10 mg/kg. All animals were fasted overnight before the initial test substance administration and sacrifice (†). ^a^p\<0.01 and ^b^p\<0.05 as compared with the intact control as shown by the Mann-Whitney U test; ^c^p\<0.01 as compared with the HFD-fed control as shown by the Mann-Whitney U test.](IJMM-40-03-0784-g00){#f1-ijmm-40-03-0784}

![Representative gross body mass and abdominal fat pads with the whole body DXA images taken from NFD- or HFD-fed mice. HFD-induced obesity, led to a marked increase in body mass and related fat accumulation in the HFD-fed control mice as compared with the NFD-fed intact mice. However, a marked inhibition of body mass and fat deposition increase was detected in the mice treated with all test substances, including YPh 125 mg/k^g^, at the analysis of gross inspections and in live DXA images, in our results. (A) Intact control: normal pellet diet-fed vehicle control mice; administered 10 ml/kg of distilled water orally. (B) HFD (vehicle) control, 10 ml/kg of distilled water administered orally with HFD supply. (C) Simvastatin, 10 mg/kg of simvastatin administered with HFD supply. (D) YPh 500, 500 mg/kg of YPh administered orally with HFD supply. (E) YPh 250, 250 mg/kg of YPh administered orally with HFD supply. (F) YPh 125, 125 mg/kg of YPh administered orally with HFD supply; NFD, normal fat pellet die; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material; DXA, dual-energy X-ray absorptiometry. Scale bar, 35 mm.](IJMM-40-03-0784-g01){#f2-ijmm-40-03-0784}

![Total body and abdominal fat densities in NFD- or HFD-fed mice. A significant (p\<0.01) increase in total body and abdominal fat density was detected in the HFD-fed controls as compared with the intact controls. On the contrary, a significant (p\<0.01) decrease in total body and abdominal fat mass was detected in the mice treated with simvastatin 10 mg/kg, and YPh 500, 250 and 125 mg/kg as compared with the HFD-fed control mice, at the analysis by DXA. Values are expressed as the means ± SD of 8 mice. NFD, normal fat pellet die; HFD, 45% kcal high-fat diet; SIM, simvastatin; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material; DXA, dual-energy X-ray absorptiometry. Simvastatin (SIM) was administrated at dose levels of 10 mg/k^g1^. ^a^p\<0.01 as compared with the intact control as shown by the LSD test; ^b^p\<0.01 as compared with the HFD-fed control as shown by the LSD test; ^c^p\<0.01 as compared with the intact control as shown by the Mann-Whitney U test; ^d^p\<0.01 as compared with the HFD control as shown by the Mann-Whitney U test.](IJMM-40-03-0784-g02){#f3-ijmm-40-03-0784}

![Representative histological images of the adipocytes, taken from NFD- or HFD-fed mice; the periovarian- and abdominal wall-deposited fat pads are shown. A significant increase in periovarian and abdominal white adipocyte diameters and thickness of each deposited fat pads was detected in the HFD-fed controls as compared with the intact controls. However, these hypertrophic changes in adipocytes and fat depositions were significantly inhibited by treatment with all test substances as compared with the HFD-fed controls. (A) Intact control: normal pellet diet-fed vehicle control mice; administered 10 ml/kg of distilled water orally. (B) HFD (vehicle) control, 10 ml/kg of distilled water administered orally with HFD supply. (C) Simvastatin, 10 mg/kg of simvastatin administered with HFD supply. (D) YPh 500, 500 mg/kg of YPh administered orally with HFD supply. (E) YPh 250, 250 mg/kg of YPh administered orally with HFD supply. (F) YPh 125, 125 mg/kg of YPh administered orally with HFD supply; NFD, normal fat pellet die; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material. All images show hematoxylin and eosin staining. Scale bars, 80 *µ*m.](IJMM-40-03-0784-g03){#f4-ijmm-40-03-0784}

![Representative general histological images of the pancreas, taken from NFD- or HFD-fed mice. Note that a marked decrease in exocrine pancreas zymogen granule contents (the percentages of exocrine pancreas occupied by zymogen granules) may be the result of the release of zymogen granules, and the increase in pancreatic islet numbers and mean diameters results from marked hyperplasia of the pancreatic islet itself or component endocrine cells that were detected in the HFD-fed controls as compared with intact controls. However, exocrine pancreas zymogen granule contents were markedly increased in the mice treated with all test substances as compared with the HFD-fed controls, apart from the simvastatin 10 mg/kg-treated mice, in which the percentages of exocrine pancreas occupied by zymogen granules were non-significantly altered as compared to those of the HFD-fed control mice. In addition, the expansion of pancreatic islets was also inhibited by treatment with all test substances. (A) Intact control: normal pellet diet-fed vehicle control mice; administered 10 ml/kg of distilled water orally. (B) HFD (vehicle) control, 10 ml/kg of distilled water administered orally with HFD supply. (C) Simvastatin, 10 mg/kg of simvastatin administered with HFD supply. (D) YPh 500, 500 mg/kg of YPh administered orally with HFD supply. (E) YPh 250, 250 mg/kg of YPh administered orally with HFD supply. (F) YPh 125, 125 mg/kg of YPh administered orally with HFD supply; NFD, normal fat pellet die; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material; IS, pancreatic islet. PD, pancreatic secretory duct. All images show hematoxylin and eosin staining. Scale bars, 80 *µ*m.](IJMM-40-03-0784-g04){#f5-ijmm-40-03-0784}

![Fecal TC and TG Content in NFD- or HFD-fed mice. Although a slight but non-significant increase in fecal TC and TG contents was detected in the HFD-fed controls as compared with the intact controls, the fecal TC and TG contents in the mice treated with all test materials, including YPh 500 mg/kg were significantly (p\<0.01) elevated as compared with the HFD-fed control mice. Values are expressed as the means ± SD of 8 mice. NFD, normal fat pellet die; HFD, 45% kcal high-fat diet; SIM, simvastatin; MET, metformin; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material; DXA, dual-energy X-ray absorptionmetry. Simvastatin (SIM) was administrated at dose levels of 10 mg/kg. ^a^p\<0.01 as compared with intact control by LSD test; ^b^p\<0.01 as compared with the HFD-fed controls as shown by the LSD test; ^c^p\<0.01 as compared with the intact controls as shown by the Mann-Whitney U test; ^d^p\<0.01 as compared with the HFD-fed controls as shown by the Mann-Whitney U test.](IJMM-40-03-0784-g05){#f6-ijmm-40-03-0784}

![Representative histological images of the liver, taken from NFD- or HFD-fed mice. Note that a marked increase in steatohepatitis, the percentage of fatty-altered regions in the liver parenchyma, was detected in the HFD-fed controls as compared with the intact controls, resulting from severe hypertrophy of hepatocyte-related to intracellular lipid depositions. However, steatohepatitis was normalized by treatment with all test substances, including YPh 250 mg/kg. In particular, the YPh 500, 250 and 125 mg/kg-treated HFD-fed mice also exhibited a noticeable decrease in the steatohepatitis-affected regions and related hepatocyte hypertrophy as compared with the HFD-fed mice. (A) Intact control: normal pellet diet-fed vehicle control mice; administered 10 ml/kg of distilled water orally. (B) HFD (vehicle) control, 10 ml/kg of distilled water administered orally with HFD supply. (C) Simvastatin, 10 mg/kg of simvastatin administered with HFD supply. (D) YPh 500, 500 mg/kg of YPh administered orally with HFD supply. (E) YPh 250, 250 mg/kg of YPh administered orally with HFD supply. (F) YPh 125, 125 mg/kg of YPh administered orally with HFD supply; NFD, normal fat pellet die; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material; CV, central vein; PT, portal triad. Scale bars, 80 *µ*m.](IJMM-40-03-0784-g06){#f7-ijmm-40-03-0784}

![Representative histological images of the kidneys, taken from NFD- or HFD-fed mice. Note that a significant increase in degenerative vacuolated renal tubules was detected in the HFD-fed controls as compared with the intact controls, resulting from lipid droplet deposited nephropathies; however, these effects were significantly normalized by treatment with all test substances, including simvastatin 10 mg/kg as compared with the HFD-fed controls. (A) Intact control: normal pellet diet-fed vehicle control mice; administered 10 ml/kg of distilled water orally. (B) HFD (vehicle) control, 10 ml/kg of distilled water administered orally with HFD supply. (C) Simvastatin, 10 mg/kg of simvastatin administered with HFD supply. (D) YPh 500, 500 mg/kg of YPh administered orally with HFD supply. (E) YPh 250, 250 mg/kg of YPh administered orally with HFD supply. (F) YPh 125, 125 mg/kg of YPh administered orally with HFD supply; NFD, normal fat pellet die; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material. All images shown hematoxylin and eosin staining. Scale bars, 80 *µ*m.](IJMM-40-03-0784-g07){#f8-ijmm-40-03-0784}

###### 

Formulas of normal and high-fat diets used in this study.

  Compositions               Normal pellet diets (g/kg diet)   High fat diets (g/kg diet)[a](#tfn1-ijmm-40-03-0784){ref-type="table-fn"}
  -------------------------- --------------------------------- ---------------------------------------------------------------------------
  Ingredient                                                   
  Casein                     200                               200
  L-Cystein                  3                                 3
  Corn starch                150                               72.8
  Sucrose                    500                               172.8
  Cellulose                  50                                50
  Soybean oil                50                                25
  Lard                       0                                 177.5
  Mineral mixture            35                                10
  Vitamin mixture            10                                10
  Choline bitartrate         2                                 2
  Energy (kcal/g)            0.21                              4.73
  Protein (% kcal/kg)        13.3                              20
  Carbohydrate (% kcal/kg)   47.4                              35
  Fat (% kcal/kg)            8.0                               45
  Fiber (% kcal/kg)          8.0                               8.0

A 45% kcal/fat pellet diet (D12451; Research Diet, New Brunswick, NJ, USA) was used as a high-fat diet (HFD) and a normal rodent pellet diet (Superfeed Co., Seoul, Korea) were used as a normal fat pellet diet.

###### 

Changes in body weight gain and mean daily food consumption in NFD- or HFD-fed mice.

  Groups         Body weight (g) at days after initial test substance administration   Body weight gain during administration period \[C-D\]       Mean daily food consumption (g)                                                                                                                                                                                                                                                     
  -------------- --------------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                                                                                                             
   Intact        28.83±1.65                                                            29.26±1.95                                                  26.79±2.13                                                  31.93±3.25                                                                                                  5.14±1.76                                                                                                   5.28±0.62
   HFD           28.68±1.79                                                            32.08±1.79[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   29.84±1.69[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   49.44±6.59[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"}                                                   19.60±7.23[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"}                                                   4.10±0.56[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"}
  Reference                                                                                                                                                                                                                                                                                                                                                                                                                            
   Simvastatin   28.74±1.30                                                            32.16±1.78[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   29.95±2.11[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   37.06±1.69[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn7-ijmm-40-03-0784){ref-type="table-fn"}   7.11±1.40[d](#tfn6-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn7-ijmm-40-03-0784){ref-type="table-fn"}    4.08±0.40[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"}
  YPh-treated                                                                                                                                                                                                                                                                                                                                                                                                                          
   500 mg/kg     28.85±1.44                                                            31.98±1.60[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   29.88±1.59[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   35.21±1.29[d](#tfn6-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn7-ijmm-40-03-0784){ref-type="table-fn"}   5.34±1.27[e](#tfn7-ijmm-40-03-0784){ref-type="table-fn"}                                                    4.05±0.71[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"}
   250 mg/kg     28.85±0.87                                                            31.94±0.88[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   29.60±1.07[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   37.41±1.10[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn7-ijmm-40-03-0784){ref-type="table-fn"}   7.81±1.34[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn7-ijmm-40-03-0784){ref-type="table-fn"}    4.17±0.53[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"}
   125 mg/kg     28.75±1.04                                                            32.08±1.28[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   29.93±1.28[b](#tfn4-ijmm-40-03-0784){ref-type="table-fn"}   40.75±2.21[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn7-ijmm-40-03-0784){ref-type="table-fn"}   10.83±2.24[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn7-ijmm-40-03-0784){ref-type="table-fn"}   4.13±0.50[c](#tfn5-ijmm-40-03-0784){ref-type="table-fn"}

Values are expressed as the mean ± SD of 8 mice. NFD, normal fat pellet diet; HFD, 45% kcal high fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material. Simvastatin was administrated at dose levels of 10 mg/kg.

All animals were fasted overnight;

p\<0.01 as compared with intact controls as shown by LSD test;

p\<0.01 and

p\<0.05 as compared with the intact controls as shown by the Mann-Whitney U test;

p\<0.01 as compared with the HFD-fed controls as shown by Mann-Whitney U test.

###### 

Changes in absolute and relative organ weight in NFD- or HFD-fed mice.

  Groups         Absolute organ weight (g)   Relative organ weight (% of body weight)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  -------------- --------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
   Intact        0.199±0.023                 1.153±0.084                                                                                                    0.178±0.009                                                                                                    0.036±0.017                                                                                                    0.059±0.020                                                                                                    0.626±0.077                                                                                                    3.634±0.358                                                   0.564±0.061                                                   0.111±0.044                                                                                                    0.183±0.048
   HFD           0.191±0.019                 1.712±0.111[a](#tfn9-ijmm-40-03-0784){ref-type="table-fn"}                                                     0.241±0.009[a](#tfn9-ijmm-40-03-0784){ref-type="table-fn"}                                                     0.742±0.157[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"}                                                    0.524±0.134[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"}                                                    0.392±0.071[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"}                                                    3.503±0.401                                                   0.493±0.062                                                   1.511±0.335[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"}                                                    1.057±0.215[a](#tfn9-ijmm-40-03-0784){ref-type="table-fn"}
  Reference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
   Simvastatin   0.193±0.021                 1.196±0.113[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}                                                    0.188±0.012[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}                                                    0.191±0.012[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.211±0.046[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.522±0.067[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   3.229±0.310[b](#tfn10-ijmm-40-03-0784){ref-type="table-fn"}   0.507±0.035                                                   0.514±0.026[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.570±0.125[a](#tfn9-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}
  YPh-treated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
   500 mg/kg     0.201±0.013                 1.135±0.088[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}                                                    0.181±0.008[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}                                                    0.088±0.013[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.148±0.041[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.571±0.049[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}                                                    3.231±0.319[b](#tfn10-ijmm-40-03-0784){ref-type="table-fn"}   0.513±0.021                                                   0.251±0.035[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.423±0.127[a](#tfn9-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}
   250 mg/kg     0.195±0.006                 1.241±0.059[b](#tfn10-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}   0.190±0.008[b](#tfn10-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}   0.220±0.040[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.245±0.062[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.521±0.021[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   3.318±0.158                                                   0.509±0.027                                                   0.586±0.092[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.659±0.178[a](#tfn9-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}
   125 mg/kg     0.196±0.014                 1.347±0.053[a](#tfn9-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}    0.200±0.009[a](#tfn9-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}    0.302±0.081[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.319±0.054[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.481±0.032[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   3.315±0.251[b](#tfn10-ijmm-40-03-0784){ref-type="table-fn"}   0.493±0.029[e](#tfn13-ijmm-40-03-0784){ref-type="table-fn"}   0.748±0.221[d](#tfn12-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn14-ijmm-40-03-0784){ref-type="table-fn"}   0.785±0.136[a](#tfn9-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn11-ijmm-40-03-0784){ref-type="table-fn"}

Values are expressed as the means ± SD of 8 mice. NFD, normal fat pellet diet; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material. Simvastatin was administrated at dose levels of 10 mg/kg;

p\<0.01 and

p\<0.05 as compared with the intact control as shown by the LSD test;

p\<0.01 and as compared with the HFD-fed control as shown by the LSD test;

p\<0.01 and

p\<0.05 as compared with the intact control as shown by the Mann-Whitney U test test;

p\<0.01 as compared with the HFD control as shown by the Mann-Whitney U test test.

###### 

Changes in the histopathology-histomorphometry of the periovarian- and abdominal wall-deposited fat pads in NFD- or HFD-fed mice.

  Groups         Periovarian fat pads                                                                                         Abdominal wall fat pads                                                                                                                                                                                                     
  -------------- ------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                                
   Intact        1.60±0.54                                                                                                    36.46±11.29                                                                                                    1.99±0.35                                                                                                    44.02±12.37
   HFD           5.57±1.00[a](#tfn16-ijmm-40-03-0784){ref-type="table-fn"}                                                    131.14±24.68[c](#tfn18-ijmm-40-03-0784){ref-type="table-fn"}                                                   6.21±0.74[c](#tfn18-ijmm-40-03-0784){ref-type="table-fn"}                                                    126.26±18.18[a](#tfn16-ijmm-40-03-0784){ref-type="table-fn"}
  Reference                                                                                                                                                                                                                                                                                                                                               
   Simvastatin   2.81±0.59[a](#tfn16-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn17-ijmm-40-03-0784){ref-type="table-fn"}   54.42±12.72[d](#tfn19-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn20-ijmm-40-03-0784){ref-type="table-fn"}   2.89±0.59[c](#tfn18-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn20-ijmm-40-03-0784){ref-type="table-fn"}   64.60±15.07[a](#tfn16-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn17-ijmm-40-03-0784){ref-type="table-fn"}
  YPh-treated                                                                                                                                                                                                                                                                                                                                             
   500 mg/kg     2.56±0.45[a](#tfn16-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn17-ijmm-40-03-0784){ref-type="table-fn"}   51.08±7.28[d](#tfn19-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn20-ijmm-40-03-0784){ref-type="table-fn"}    2.49±0.46[c](#tfn18-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn20-ijmm-40-03-0784){ref-type="table-fn"}   50.21±9.17[b](#tfn17-ijmm-40-03-0784){ref-type="table-fn"}
   250 mg/kg     3.08±0.50[a](#tfn16-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn17-ijmm-40-03-0784){ref-type="table-fn"}   60.05±7.46[c](#tfn18-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn20-ijmm-40-03-0784){ref-type="table-fn"}    3.12±0.31[c](#tfn18-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn20-ijmm-40-03-0784){ref-type="table-fn"}   68.10±10.28[a](#tfn16-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn17-ijmm-40-03-0784){ref-type="table-fn"}
   125 mg/kg     3.81±0.79[a](#tfn16-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn17-ijmm-40-03-0784){ref-type="table-fn"}   77.72±19.23[c](#tfn18-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn20-ijmm-40-03-0784){ref-type="table-fn"}   4.71±0.80[c](#tfn18-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn20-ijmm-40-03-0784){ref-type="table-fn"}   87.73±14.28[a](#tfn16-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn17-ijmm-40-03-0784){ref-type="table-fn"}

Values are expressed as the means ± SD of 8 mice. NFD, normal fat pellet diet; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material. Simvastatin was administrated at dose levels of 10 mg/kg.

p\<0.01 as compared with the intact control as shown by LSD test;

p\<0.01 as compared with the HFD-fed control as shown by the LSD test;

p\<0.01 and

p\<0.05 as compared with the intact control as shown by the Mann-Whitney U test test;

p\<0.01 as compared with the HFD-fed control as shown by the Mann-Whitney U test test.

###### 

Changes in histopathology-histomorphometry of the pancreas, liver and kidneys in the NFD-fed or HFD-fed mice.

  Groups         Zymogen granules (%/mm^2^ of exocrine)   Liver steatosis (%/mm^2^ of hepatic tissues)                                                                   Mean hepatocyte diameters (*µ*m/cell)                                                                         Degenerative renal tubule numbers (%)
  -------------- ---------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                             
   Intact        53.64±10.09                              7.27±2.36                                                                                                      17.72±1.91                                                                                                    3.13±1.64
   HFD           13.46±3.28^c^                            76.36±9.61[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"}                                                     53.45±12.48[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"}                                                   73.88±14.66[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"}
  Reference                                                                                                                                                                                                                                                                            
   Simvastatin   16.23±5.42^c^                            32.45±10.25[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}   22.46±3.28[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}   35.75±14.44[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}
  YPh-treated                                                                                                                                                                                                                                                                          
   500 mg/kg     43.90±6.85^d,e^                          19.95±4.89[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}    21.29±2.36[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}   19.00±7.6^5^[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}
   250 mg/kg     36.69±5.93^c,e^                          31.99±10.05[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}   25.79±3.75[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}   39.25±11.62[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}
   125 mg/kg     29.91±7.28^c,e^                          50.50±11.60[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}   32.36±6.36[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}   44.38±12.15[a](#tfn22-ijmm-40-03-0784){ref-type="table-fn"},[b](#tfn23-ijmm-40-03-0784){ref-type="table-fn"}

Values are expressed as the means ± SD of 8 mice. NFD, normal fat pellet diet; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material. Simvastatin was administrated at dose levels of 10 mg/kg.

p\<0.01 as compared with the intact controls as shown by the Mann-Whitney U test test;

p\<0.01 as compared with the HFD-fed controls as shown by the Mann-Whitney U test test.

###### 

Changes on serum lipid contents in NFD- or HFD-fed mice.

  Groups         Total cholesterol (mg/dl)                                                                                       Triglyceride (mg/dl)                                                                                            Low-density lipoprotein (mg/dl)                                                                               High-density lipoprotein (mg/dl)
  -------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                                     
   Intact        113.88±21.26                                                                                                    50.63±18.52                                                                                                     16.13±1.64                                                                                                    105.00±22.61
   HFD           279.13±36.98[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"}                                                    215.13±23.42[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"}                                                    49.13±9.49[d](#tfn28-ijmm-40-03-0784){ref-type="table-fn"}                                                    23.50±10.25[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"}
  Reference                                                                                                                                                                                                                                                                                                                                                    
   Simvastatin   172.13±36.21[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}   119.25±34.51[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}   22.63±4.37[d](#tfn28-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn29-ijmm-40-03-0784){ref-type="table-fn"}   74.38±10.64[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}
  YPh treated                                                                                                                                                                                                                                                                                                                                                  
   500 mg/kg     158.75±27.75[b](#tfn26-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}   100.88±24.33[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}   20.75±1.91[d](#tfn28-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn29-ijmm-40-03-0784){ref-type="table-fn"}   83.13±13.73[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}
   250 mg/kg     192.13±37.31[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}   131.13±23.90[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}   24.88±3.68[d](#tfn28-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn29-ijmm-40-03-0784){ref-type="table-fn"}   68.50±16.96[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}
   125 mg/kg     213.75±33.40[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}   162.25±37.09[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}   31.75±7.09[d](#tfn28-ijmm-40-03-0784){ref-type="table-fn"},[e](#tfn29-ijmm-40-03-0784){ref-type="table-fn"}   49.75±14.20[a](#tfn25-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn27-ijmm-40-03-0784){ref-type="table-fn"}

Values are expressed as the means ± SD of 8 mice. NFD, normal fat pellet diet; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material. Simvastatin was administrated at dose levels of 10 mg/kg;

p\<0.01 and

p\<0.05 as compared with the intact controls as shown by the LSD test;

p\<0.01 as compared with the HFD-fed control as shown by the LSD test;

p\<0.01 as compared with the intact controls as shown by the Mann-Whitney U test test;

p\<0.01 as compared with the HFD control as shown by the Mann-Whitney U test test.

###### 

Changes in serum AST, ALT, BUN and creatine levels in NFD- or HFD-fed mice.

  Groups         AST (IU/l)                                                                                                      ALT (IU/l)                                                                                                      BUN (mg/dl)                                                                                                    Creatinine (mg/dl)
  -------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                                      
   Intact        74.50±14.19                                                                                                     33.50±11.41                                                                                                     34.75±10.39                                                                                                    0.66±0.21
   HFD           226.75±23.23[d](#tfn34-ijmm-40-03-0784){ref-type="table-fn"}                                                    169.00±18.67[a](#tfn31-ijmm-40-03-0784){ref-type="table-fn"}                                                    97.38±16.05[a](#tfn31-ijmm-40-03-0784){ref-type="table-fn"}                                                    2.19±0.24[d](#tfn34-ijmm-40-03-0784){ref-type="table-fn"}
  Reference                                                                                                                                                                                                                                                                                                                                                     
   Simvastatin   121.50±30.34[d](#tfn34-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn36-ijmm-40-03-0784){ref-type="table-fn"}   77.00±18.55[a](#tfn31-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn33-ijmm-40-03-0784){ref-type="table-fn"}    61.25±9.22[a](#tfn31-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn33-ijmm-40-03-0784){ref-type="table-fn"}    1.20±0.08[d](#tfn34-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn36-ijmm-40-03-0784){ref-type="table-fn"}
  YPh-treated                                                                                                                                                                                                                                                                                                                                                   
   500 mg/kg     96.50±16.20[e](#tfn35-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn36-ijmm-40-03-0784){ref-type="table-fn"}    61.38±21.25[a](#tfn31-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn33-ijmm-40-03-0784){ref-type="table-fn"}    50.00±11.90[b](#tfn32-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn33-ijmm-40-03-0784){ref-type="table-fn"}   0.96±0.25[e](#tfn35-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn36-ijmm-40-03-0784){ref-type="table-fn"}
   250 mg/kg     127.50±18.75[d](#tfn34-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn36-ijmm-40-03-0784){ref-type="table-fn"}   87.50±14.52[a](#tfn31-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn33-ijmm-40-03-0784){ref-type="table-fn"}    63.13±10.41[a](#tfn31-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn33-ijmm-40-03-0784){ref-type="table-fn"}   1.34±0.23[d](#tfn34-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn36-ijmm-40-03-0784){ref-type="table-fn"}
   125 mg/kg     167.00±22.46[d](#tfn34-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn36-ijmm-40-03-0784){ref-type="table-fn"}   111.88±11.93[a](#tfn31-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn33-ijmm-40-03-0784){ref-type="table-fn"}   74.13±10.11[a](#tfn31-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn33-ijmm-40-03-0784){ref-type="table-fn"}   1.60±0.26[d](#tfn34-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn36-ijmm-40-03-0784){ref-type="table-fn"}

Values are expressed as the means ± SD of 8 mice. NFD, normal fat pellet diet; HFD, 45% kcal high-fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material. Simvastatin was administrated at dose levels of 10 mg/kg. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen.

p\<0.01 and

p\<0.05 as compared with the intact control as shown by the LSD test;

p\<0.01 as compared with the HFD-fed control as shown by the LSD test;

p\<0.01 and

p\<0.05 as compared with the intact control as shown by the Mann-Whitney U test;

p\<0.01 as compared with the HFD-fed control as shown by the Mann-Whitney U test.

###### 

Changes on the liver lipid peroxidation and antioxidant defense systems in NFD- or HFD-fed mice.

  Groups         Lipid peroxidation                                                                                            Antioxidant defense system                                                                                                                                                                                                  
  -------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Controls                                                                                                                                                                                                                                                                                                                                                 
   Intact        11.57±1.89                                                                                                    35.91±6.38                                                                                                    30.81±7.18                                                                                                    3.31±1.02
   HFD           31.14±7.01[a](#tfn38-ijmm-40-03-0784){ref-type="table-fn"}                                                    10.99±2.29[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"}                                                    10.33±2.51[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"}                                                    0.87±0.13[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"}
  Reference                                                                                                                                                                                                                                                                                                                                                
   Simvastatin   19.59±3.90[a](#tfn38-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn40-ijmm-40-03-0784){ref-type="table-fn"}   22.31±3.52[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}   18.64±1.77[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}   2.03±0.35[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}
  YPh-treated                                                                                                                                                                                                                                                                                                                                              
   500 mg/kg     16.63±3.09[b](#tfn39-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn40-ijmm-40-03-0784){ref-type="table-fn"}   30.65±6.50[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}                                                    22.56±3.93[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}   2.29±0.49[e](#tfn42-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}
   250 mg/kg     21.20±3.16[a](#tfn38-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn40-ijmm-40-03-0784){ref-type="table-fn"}   21.86±2.94[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}   17.83±2.85[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}   1.97±0.13[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}
   125 mg/kg     22.64±3.27[a](#tfn38-ijmm-40-03-0784){ref-type="table-fn"},[c](#tfn40-ijmm-40-03-0784){ref-type="table-fn"}   16.26±3.03[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}   16.16±1.53[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}   1.62±0.39[d](#tfn41-ijmm-40-03-0784){ref-type="table-fn"},[f](#tfn43-ijmm-40-03-0784){ref-type="table-fn"}

Values are expressed as the means ± SD of 8 mice. NFD, normal fat pellet diet; HFD, 45% kcal high fat diet; YPh, yellow(head) catfish or Korean bullhead (*Tachysurus fulvidraco*) protein hydrolysates, test material; SOD, superoxide dismutase. Simvastatin was administrated at dose levels of 10 mg/kg.

p\<0.01 and

p\<0.05 as compared with the intact controls as shown by the LSD test;

p\<0.01 as compared with the HFD-fed controls as shown by the LSD test;

p\<0.01 and

p\<0.05 as compared with the intact controls as shown by the Mann-Whitney U test;

p\<0.01 as compared with the HFD-fed controls as shown by the Mann-Whitney U test.

[^1]: Contributed equally
